Reactivating PTEN to Impair Glioma Stem Cells by Inhibiting Cytosolic Iron-Sulfur Assembly

Using the Suppression of Cytoplasmic Iron-Sulfur Cluster Assembly to Restore PTEN and Inhibit Glioma Stem Cells Background Glioblastoma (GBM) is one of the most lethal primary brain tumors. Glioma stem cells (GSCs) not only initiate and sustain the malignant phenotype but also enhance treatment resistance. Although PTEN frequently mutates in gliobl...

Mechanism of SRC Inhibition in IDH-Mutant Cholangiocarcinoma

Scientists Reveal the Anti-Tumor Mechanism of Src Inhibitors in IDH Mutant Cholangiocarcinoma Background Introduction In recent years, the incidence of intrahepatic cholangiocarcinoma (ICC) has been rising worldwide. ICC is a highly invasive tumor usually lacking noticeable symptoms in the early stages, with cases often being inoperable by the time...

The Crosstalk Between Macrophages and Cancer Cells Potentiates Pancreatic Cancer Cachexia

Interactive Mechanisms Between Cancer Cells and Macrophages Facilitate Pancreatic Cancer Cachexia Background Pancreatic cancer is currently the third leading cause of cancer-related death in the United States and is expected to become the second leading cause of cancer death within the next decade. Unfortunately, more than 80% of pancreatic cancer ...

Tumor Cell-Intrinsic Epigenetic Dysregulation Shapes Cancer-Associated Fibroblasts Heterogeneity to Metabolically Support Pancreatic Cancer

Tumor Cell-Intrinsic Epigenetic Dysregulation Shapes Cancer-Associated Fibroblasts Heterogeneity to Metabolically Support Pancreatic Cancer

Intrinsic Epigenetic Dysregulation in Tumor Cells Shapes Cancer-Associated Fibroblasts Heterogeneity to Metabolically Support Pancreatic Cancer Authors Ningning Niu, Qingshen Xu, Wang Zheng, …, Kurong Jiang, Fengshi Yu, Xue Xu Jing published an article titled “Intrinsic Epigenetic Dysregulation in Tumor Cells Shapes Cancer-Associated Fibroblasts He...

Putting the STING Back into BH3-Mimetic Drugs for TP53-Mutant Blood Cancers

Applying STING Function to BH3-Mimetic Drugs for Treating TP53 Mutant Blood Cancers In the recently published article in Cancer Cell titled “Putting the sting back into BH3-mimetic drugs for TP53-mutant blood cancers,” Sarah T. Diepstraten and colleagues conducted in-depth research to explore how to enhance the efficacy of BH3-mimetic drugs in TP53...

Molecular Targets of Glucocorticoids that Elucidate Their Therapeutic Efficacy in Aggressive Lymphomas

Analysis of Molecular Targets of Glucocorticoids in the Treatment of Aggressive Lymphomas Academic Background Glucocorticoids (GCs) have been used for over 70 years in the treatment of hematological malignancies, but their mechanisms of action remain unclear. Clinically, glucocorticoids show significant efficacy in treating lymphomas but not in mye...